The Final Height of Turnerâ€™s Patients in Algeria
Ali El Mahdi Haddam1
Nora Soumeya Fedala2
1. Department of endocrinology bologhine hospital 16000
2. Department of endocrinology Bab el oued hospital
International Journal of Clinical Case Reports, 2015, Vol. 5, No. 20 doi: 10.5376/ijccr.2015.05.0020
Received: 18 Mar., 2015 Accepted: 03 May, 2015 Published: 22 May, 2015
© 2015 BioPublisher Publishing Platform
This is an open access article published under the terms of the Creative Commons Attribution License
, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Preferred citation for this article:
Haddam et al., 2015, The Final Height of Turner’s Patients in Algeria, International Journal of Clinical Case Reports, Vol.5, No.20 1-4 (doi: 10.5376/ijccr.2015.05.0020)
Summary Turner syndrome is the most common chromosomal abnormality in women. It is linked to the absence or abnormality of one of the two X chromosomes and characterized by short stature, gonadal dysgenesis, and a variety of dysmorphic traits and associated anomalies. . We report the results on final height in 30 patients who have reached adulthood and who have been since their diagnosis. All patients received treatment with biosynthetic growth hormone. Mean ± SD (range) age at diagnosis was 9 ± 0.19(4- 17) years. Height at diagnosis was -4.0 ± 0,1 SD below the population mean (M) and -3DS below the parental Target Height (TH). Final height was -3, 5 ± SD and -2.5 SD below M and TH respectively.
Growth failure; Short stature; Turner syndrome; Growth hormone; Karyotype
International Journal of Clinical Case Reports
• Volume 5